{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:15:13Z","timestamp":1747977313861,"version":"3.41.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02788-6","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T18:44:28Z","timestamp":1747939468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis surface B antigen clearance induced by long-term tenofovir disoproxil fumarate monotherapy in chronic hepatitis B treatment: a meta-analysis and longitudinal modeling analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Weizhe","family":"Jian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junsheng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2788_CR1","unstructured":"Global hepatitis report 2024: action for access in low- and middle-income countries [Internet]. 1st ed. Geneva: World Health Organization. 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240091672"},{"issue":"1","key":"2788_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang K, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology"},{"key":"2788_CR3","doi-asserted-by":"crossref","unstructured":"EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"000","key":"2788_CR4","doi-asserted-by":"publisher","first-page":"000","DOI":"10.14218\/JCTH.2023.00320","volume":"000","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;000(000):000\u2013000.","journal-title":"J Clin Transl Hepatol"},{"key":"2788_CR5","doi-asserted-by":"publisher","first-page":"637126","DOI":"10.3389\/fmed.2021.637126","volume":"8","author":"S Yang","year":"2021","unstructured":"Yang S, Ma X, Cai C, Wang H, Xiao F, Yu C. Tenofovir disoproxil fumarate is superior to Entecavir in reducing hepatitis B surface antigen for chronic hepatitis B in China: 2-Year comprehensive comparative result of a matched comparative study. Front Med. 2021;8:637126.","journal-title":"Front Med"},{"issue":"5","key":"2788_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-023-01843-2","volume":"83","author":"ML Chang","year":"2023","unstructured":"Chang ML, Liaw YF. Emerging therapies for chronic hepatitis B and the potential for a functional cure. Drugs. 2023;83(5):367\u201388.","journal-title":"Drugs"},{"issue":"3","key":"2788_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","volume":"72","author":"M Cornberg","year":"2020","unstructured":"Cornberg M, Lok ASF, Terrault NA, Zoulim F, Berg T, Brunetto MR, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV treatment endpoints conference\u2021. J Hepatol. 2020;72(3):539\u201357.","journal-title":"J Hepatol"},{"issue":"4","key":"2788_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","volume":"20","author":"SG Lim","year":"2023","unstructured":"Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol. 2023;20(4):238\u201353.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"2788_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","volume":"69","author":"F Rinker","year":"2018","unstructured":"Rinker F, Zimmer CL, H\u00f6ner Zu Siederdissen C, Manns MP, Kraft ARM, Wedemeyer H, et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Hepatol. 2018;69(3):584\u201393.","journal-title":"J Hepatol"},{"key":"2788_CR10","doi-asserted-by":"crossref","unstructured":"Jiaye L, Tingyan W, Wei Z, Yongqian C, Qing H, Fu-Sheng W. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2020;14(6):958\u201372.","DOI":"10.1007\/s12072-020-10099-x"},{"issue":"1","key":"2788_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12072-022-10415-7","volume":"17","author":"M Li","year":"2023","unstructured":"Li M, Li Q, Qu J, Yang H, Lv T, Kong Y, et al. The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2023;17(1):52\u201362.","journal-title":"Hepatol Int"},{"issue":"7","key":"2788_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jvh.13283","volume":"27","author":"MA Fonseca","year":"2020","unstructured":"Fonseca MA, Ling JZJ, Al-Siyabi O, Co\u2010Tanko V, Chan E, Lim SG. The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta\u2010analysis. J Viral Hepatitis. 2020;27(7):650\u201362.","journal-title":"J Viral Hepatitis"},{"issue":"6","key":"2788_CR13","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","volume":"14","author":"J Liu","year":"2020","unstructured":"Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2020;14(6):958\u201372.","journal-title":"Hepatol Int"},{"issue":"6","key":"2788_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/emermed-2020-209567","volume":"37","author":"M Amir-Behghadami","year":"2020","unstructured":"Amir-Behghadami M, Janati A, Population. Intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020;37(6):387\u2013387.","journal-title":"Emerg Med J"},{"key":"2788_CR15","doi-asserted-by":"publisher","unstructured":"Schwarzer G, Carpenter JR, R\u00fccker G. Meta-analysis with R [Internet]. Cham: Springer International Publishing.2015 [cited 2024 Oct 14]; (Use R!). Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-3-319-21416-0","DOI":"10.1007\/978-3-319-21416-0"},{"issue":"12","key":"2788_CR16","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/jac\/dkr388","volume":"66","author":"J Fung","year":"2011","unstructured":"Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011;66(12):2715\u201325.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2788_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.livres.2017.06.002","volume":"1","author":"SGR Kho-Herman","year":"2017","unstructured":"Kho-Herman SGR, Chan HLY. Stopping nucleos(t)ide analog treatment in chronic hepatitis B \u2014 Who and when? Liver Res. 2017;1(2):135\u20139.","journal-title":"Liver Res"},{"issue":"s1","key":"2788_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/liv.12398","volume":"34","author":"C P\u00e9rez-Cameo","year":"2014","unstructured":"P\u00e9rez-Cameo C, Pons M, Esteban R. New therapeutic perspectives in HBV: when to stop NA s. Liver Int. 2014;34(s1):146\u201353.","journal-title":"Liver Int"},{"issue":"3","key":"2788_CR19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/hep.30474","volume":"70","author":"J Liu","year":"2019","unstructured":"Liu J, Li T, Zhang L, Xu A. The role of hepatitis B surface antigen in Nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis B: A systematic review. Hepatology. 2019;70(3):1045\u201355.","journal-title":"Hepatology"},{"key":"2788_CR20","doi-asserted-by":"crossref","unstructured":"Moini M, Fung S. HBsAg Loss as a treatment endpoint for chronic HBV infection: HBV cure. Viruses. 2022;14(4):657.","DOI":"10.3390\/v14040657"},{"issue":"3","key":"2788_CR21","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/ijms22031456","volume":"22","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination of Entecavir or Tenofovir with pegylated Interferon-\u03b1 for Long-Term reduction in hepatitis B surface antigen levels: simultaneous, sequential, or Add-on combination therapy. IJMS. 2021;22(3):1456.","journal-title":"IJMS"},{"key":"2788_CR22","doi-asserted-by":"crossref","unstructured":"Terrault N, Lok A, McMahon B, Chang K, Hwang J, Jonas M et al. Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. 2019.","DOI":"10.1002\/hep.29800"},{"issue":"10","key":"2788_CR23","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/liv.14155","volume":"39","author":"P Marcellin","year":"2019","unstructured":"Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, et al. Ten-year efficacy and safety of Tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019;39(10):1868\u201375.","journal-title":"Liver Int"},{"issue":"1","key":"2788_CR24","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.1038\/s41598-017-13747-9","volume":"7","author":"J Huang","year":"2017","unstructured":"Huang J, Zhang K, Chen W, Liao J, Luo X, Chen R. Switching to PegIFN\u03b1-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs. Sci Rep. 2017;7(1):13383.","journal-title":"Sci Rep"},{"issue":"5","key":"2788_CR25","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/hep.27586","volume":"61","author":"WP Brouwer","year":"2015","unstructured":"Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, et al. Adding pegylated interferon to Entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology. 2015;61(5):1512\u201322.","journal-title":"Hepatology"},{"key":"2788_CR26","doi-asserted-by":"crossref","unstructured":"He Y, Lin W, Li H, Gu F, Zhong H, Lan Y et al. Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV\/HIV during antiretroviral therapy in Guangdong, China. Chin Med J. 2023;136(22):2686\u201393.","DOI":"10.1097\/CM9.0000000000002886"},{"issue":"22","key":"2788_CR27","first-page":"2744","volume":"135","author":"H Xia","year":"2022","unstructured":"Xia H, Gao L, Hu Y, Huang X, Wu H, Ma P. High rates of hepatitis B virus (HBV) functional cure among HIV\/HBV coinfected Chinese adults on antiretroviral therapy. Chin Med J (Engl). 2022;135(22):2744\u20136.","journal-title":"Chin Med J (Engl)"},{"key":"2788_CR28","doi-asserted-by":"crossref","unstructured":"Zhang Q, Wang H, Jin Y, Zhou N, Sun L, Wu H et al. Incidence and predictors of HBV functional cure in patients with HIV\/HBV coinfection: A retrospective cohort study. Front Cell Infect Microbiol. 2023;13:1130485.","DOI":"10.3389\/fcimb.2023.1130485"},{"issue":"4","key":"2788_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/BF01061691","volume":"21","author":"NL Dayneka","year":"1993","unstructured":"Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21(4):457\u201378.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"9","key":"2788_CR30","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","volume":"93","author":"MA Nowak","year":"1996","unstructured":"Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA. 1996;93(9):4398\u2013402.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2788_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jtbi.2018.03.025","volume":"447","author":"F Fatehi Chenar","year":"2018","unstructured":"Fatehi Chenar F, Kyrychko YN, Blyuss KB. Mathematical model of immune response to hepatitis B. J Theor Biol. 2018;447:98\u2013110.","journal-title":"J Theor Biol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02788-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02788-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02788-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T18:44:41Z","timestamp":1747939481000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02788-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2788"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02788-6","relation":{},"ISSN":["1743-422X"],"issn-type":[{"type":"electronic","value":"1743-422X"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted conforming to the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice Guidelines. The analysis plan was approved by institutional review boards and independent ethics committees. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}